Other Rare Pancreatic Endocrine Neoplasms

Slide 1 · Other Rare Pancreatic Endocrine Neoplasms

Clinicopathologic patterns, tumor biology, and differential diagnosis

Pancreatic neuroendocrine neoplasms • Hormone-associated clinicopathologic patterns

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Recognize the hormone–syndrome associations of five rare pancreatic endocrine neoplasms.

Differentiate hypersecretory syndromes from hormonally silent mass lesions.

Relate rare subtypes to the broader biology and grading of pancreatic neuroendocrine neoplasms.

Use symptom clusters to choose focused biochemical tests and appropriate differentials.

Slide 3 · The pancreatic neuroendocrine family

Pancreatic endocrine neoplasm

Neoplastic endocrine cells in or near the pancreas

Hormone secretion

Clinically functioning or clinically silent

Behavior assessment

Proliferation and differentiation matter independently of syndrome

Slide 4 · Functionality is not the same as malignancy

Functional neoplasm

A hormone causes a recognizable clinical syndrome.

Clinical effects can reveal a small lesion.

Biochemical evidence must match the syndrome.

Nonfunctional or clinically silent neoplasm

Secreted hormone may not cause symptoms.

A mass may be the presenting finding.

Tumor behavior still requires assessment.

Slide 5 · PanNENs in the pancreatic tumor spectrum

PanNENs are uncommon relative to exocrine pancreatic tumors.

The source estimates about 2% of pancreatic neoplasms are PanNENs.

The rare hormone-defined subtypes are only part of this already uncommon group.

Clinical implication

Do not equate a pancreatic mass with a functional endocrine neoplasm.

Slide 6 · Possible anatomic distribution

Within pancreas

Tumors may arise throughout pancreatic tissue

Peripancreatic tissues

PanNENs may involve adjacent tissues

Hormone syndrome

Symptoms alone cannot precisely localize the source

Slide 7 · Microscopic uniformity can be deceptive

Typical well-differentiated pattern

Neoplastic cells may appear relatively monotonous.

Marked pleomorphism may be absent.

Appearance alone is not a reliable behavior predictor.

What the pathologist still evaluates

Mitotic activity and Ki-67 index.

Tumor differentiation and subtype.

Invasion or metastasis when documented.

Slide 8 · Proliferation contributes to PanNET grading

Mitotic activity

Quantifies tumor-cell divisions

Ki-67 index

Estimates the proliferating fraction

Histologic grade

Higher proliferation suggests more aggressive potential

Slide 9 · Grade and differentiation answer different questions

Well-differentiated PanNET

Preserves neuroendocrine-type morphology.

Proliferative activity supports grading.

Bland appearance does not guarantee indolence.

Poorly differentiated PanNEC

Small-cell or large-cell morphology.

Usually highly proliferative.

Separate category from a well-differentiated NET.

Slide 10 · Three recurring molecular themes

Molecular theme

Examples in Robbins

Conceptual consequence

MEN1 tumor suppressor

MEN1 alterations

Neuroendocrine tumor predisposition

mTOR signaling

PTEN, TSC2 loss of function

Growth-promoting pathway activation

Telomere maintenance

ATRX, DAXX inactivation

Alternative telomere lengthening

Slide 11 · MEN1: Hereditary syndrome and sporadic tumor

Inherited MEN1 setting

Multiple endocrine glands may be involved

Sporadic PanNEN

Somatic MEN1 alteration may occur

Interpretation

Do not infer inherited MEN1 from one tumor alone

Slide 12 · MTOR activation is one oncogenic route

PTEN / TSC2

Loss-of-function alterations

MTOR signaling

Oncogenic activation

PanNEN growth

Cellular growth advantage

Slide 13 · ATRX / DAXX and telomere maintenance

ATRX or DAXX

Inactivating alteration

ALT pathway

Alternative lengthening of telomeres

Tumor-cell survival

Telomeres maintained without telomerase

Slide 14 · How these rare tumors become recognizable

Subtype

Reported secretion

Characteristic clue

Glucagonoma

Glucagon

Erythema + mild diabetes + anemia

Somatostatinoma

Somatostatin

Diabetes + gallstones + steatorrhea + hypochlorhydria

VIPoma

VIP

Watery diarrhea + hypokalemia + achlorhydria

Pancreatic serotonin-producing tumor

Serotonin

Rare atypical carcinoid syndrome

Pancreatic polypeptide tumor

Pancreatic polypeptide

Mass lesion without hormone syndrome

Slide 15 · Glucagonoma: The source-defined phenotype

α-cell tumor

Glucagon secretion

Marked glucagon excess

Very high plasma glucagon

Clinical triad

Mild diabetes, characteristic rash, anemia

Slide 16 · Necrolytic migratory erythema is the skin clue

The characteristic skin eruption is termed necrolytic migratory erythema.

Its value is greatest when recognized with diabetes and anemia.

A compatible cutaneous finding should prompt consideration of glucagon excess.

Diagnostic reasoning

A dermatologic manifestation can be the clue to an endocrine pancreatic neoplasm.

Slide 17 · Glucagonoma-associated diabetes is described as mild

Observed finding

Mild diabetes mellitus belongs to the glucagonoma syndrome.

The pancreatic hormone glucagon is elevated.

The source does not provide glucose cutoffs.

Interpretive limit

Diabetes alone is common and nonspecific.

A triad carries more diagnostic weight than one feature.

Confirmation requires an endocrine evaluation.

Slide 18 · Anemia completes the classic glucagonoma cluster

Anemia accompanies the skin eruption and diabetes in the Robbins description.

Anemia by itself is not distinctive for glucagonoma.

Together, the three findings form a clinically useful pattern.

Pattern recognition

Skin + glucose disturbance + anemia → consider glucagonoma.

Slide 19 · Age and sex: Supporting, not defining, clues

Glucagonomas most often in perimenopausal or postmenopausal females.

This is a demographic tendency, not a diagnostic criterion.

Laboratory and clinical syndrome recognition remain more informative.

Slide 20 · Glucagonoma: From clinical suspicion to evidence

Syndrome recognition

Skin eruption + dysglycemia + anemia

Biochemical assessment

Extremely high plasma glucagon

Tumor assessment

Identify and evaluate the lesion

Slide 21 · Clinical application: Glucagonoma

Teaching vignette

A woman develops mild diabetes, anemia, and a distinctive recurrent skin eruption. Endocrine testing demonstrates markedly increased circulating glucagon.

Diagnostic question

Which rare pancreatic endocrine neoplasm best explains this constellation?

Answer: Glucagonoma

The skin finding, dysglycemia, and anemia form the source-described syndrome. • Marked glucagon elevation links the clinical cluster to α-cell hormone secretion.

Slide 22 · Glucagonoma vs insulinoma

Glucagonoma

Glucagon overproduction.

Typically mild diabetes.

Necrolytic migratory erythema and anemia.

Insulinoma (adjacent topic)

Excess insulin secretion.

Hypoglycemic episodes.

Confusion or loss of consciousness during attacks.

Slide 23 · What the glucagonoma pattern does not establish

Question

What the syndrome supports

What it does not prove

Tumor identity

Suggests glucagonoma

Does not locate a lesion by itself

Biochemistry

Plasma glucagon is relevant

No validated cutoff supplied here

Oncologic status

Functional tumor phenotype

Does not establish grade or metastasis

Slide 24 · Somatostatinoma: δ-cell secretory phenotype

δ-cell tumor

Somatostatin secretion

High hormone level

Plasma somatostatin must be elevated

Multisystem syndrome

Diabetes, gallstones, steatorrhea, low gastric acid

Slide 25 · Four reported components of somatostatinoma

Diabetes mellitus

Metabolic disturbance

Cholelithiasis

Gallstones

Steatorrhea

Fatty stools

Hypochlorhydria

Reduced gastric acidity

Slide 26 · Diabetes is shared by two rare subtypes

Glucagonoma

Dysglycemia is characterized as mild diabetes.

Skin eruption and anemia supply discrimination.

Extremely high plasma glucagon supports diagnosis.

Somatostatinoma

Diabetes may also occur.

Cholelithiasis, steatorrhea and hypochlorhydria distinguish the syndrome.

High somatostatin is required for diagnosis.

Slide 27 · Gastric acid direction differentiates syndromes

Somatostatinoma

Hypochlorhydria is associated with the syndrome.

Gastric acid is reduced.

Other clues: Diabetes, gallstones and steatorrhea.

Gastrinoma (adjacent topic)

Hypergastrinemia increases gastric acid secretion.

Refractory or unusual peptic ulceration is prominent.

This contrast can orient the differential.

Slide 28 · Somatostatinoma: Biochemical confirmation

Suspect syndrome

Diabetes ± gallstones ± steatorrhea

Hormone testing

High plasma somatostatin

Lesion search

Localization may be challenging

Slide 29 · Localization can be challenging

Somatostatinomas may be very difficult to localize before surgery.

A convincing clinical syndrome does not automatically reveal anatomic position.

Keep biochemical classification distinct from imaging and operative localization.

Source limitation

The supplied passage does not specify preferred imaging sequences.

Slide 30 · Clinical application: Somatostatinoma

Teaching vignette

A patient with diabetes also has gallstones, fatty stools, and reduced gastric acidity. Biochemical evaluation detects elevated circulating somatostatin.

Diagnostic question

Which rare functional pancreatic endocrine tumor is most compatible?

Answer: Somatostatinoma

The four manifestations match the described somatostatinoma constellation. • Hormone elevation provides subtype-specific support.

Slide 31 · Glucagonoma and somatostatinoma: Fast comparison

Finding

Glucagonoma

Somatostatinoma

Diabetes

Mild diabetes described

Diabetes described

Cutaneous lesion

Necrolytic migratory erythema

Not a defining clue in excerpt

Anemia

Syndromic feature

Not listed here

Gallstones, steatorrhea

Not defining in excerpt

Syndromic features

Hormone

Very high glucagon

High somatostatin

Slide 32 · VIPoma: A hormone-driven secretory syndrome

VIP-producing tumor

Vasoactive intestinal peptide release

Fluid secretion

Severe watery diarrhea

WDHA syndrome

Watery diarrhea, hypokalemia, achlorhydria

Slide 33 · Decode WDHA syndrome

WD: Watery diarrhea

Secretory intestinal fluid loss

H: Hypokalemia

Potassium depletion accompanies diarrhea

A: Achlorhydria

Absent gastric acid

Clinical pattern

VIP-associated secretory syndrome

Slide 34 · Watery secretory diarrhea drives the evaluation

VIPoma is a recognized cause of severe secretory diarrhea.

Diarrhea may dominate the clinical presentation before a tumor is localized.

A source-directed biochemical test is a VIP assay.

Slide 35 · VIP excess links the tumor to WDHA

Tumor secretes VIP

Hormonal initiating event

Watery diarrhea

Gastrointestinal secretory phenotype

Hypokalemia

Electrolyte disturbance within WDHA

Slide 36 · VIPoma and somatostatinoma: Overlapping GI clues

VIPoma

Watery diarrhea is the dominant clue.

Hypokalemia is part of the defining syndrome.

Achlorhydria is described.

Somatostatinoma

Steatorrhea is part of the syndrome.

Gallstones and diabetes aid recognition.

Hypochlorhydria is described.

Slide 37 · Achlorhydria vs hypochlorhydria

VIPoma

Achlorhydria appears in WDHA.

The acid output descriptor is absent gastric acidity.

The leading presentation is watery diarrhea.

Somatostatinoma

Hypochlorhydria is described.

The acid output descriptor is reduced acidity.

Gallstones, steatorrhea, diabetes aid recognition.

Slide 38 · When to order a VIP assay

Robbins recommends a VIP assay for all patients with severe secretory diarrhea.

A biochemical result must be interpreted with the syndrome and lesion evaluation.

Do not restrict suspicion to pancreatic masses alone.

Slide 39 · VIP syndrome can arise outside the pancreas

Origin mentioned in Robbins

Relevant point

Pancreatic VIPoma

Produces VIP and characteristic WDHA syndrome

Neuroblastoma

Neural-crest neoplasm may be linked to VIP syndrome

Ganglioneuroblastoma

Also cited as a possible association

Ganglioneuroma

Also cited as a possible association

Pheochromocytoma

Also associated with VIPoma syndrome

Slide 40 · Anatomic diagnosis requires two distinct questions

Does VIP excess explain the syndrome?

Biochemical / clinical classification

Where is the source of VIP?

Pancreatic or alternative neoplasm

Does the lesion spread?

Invasion and metastatic status

Slide 41 · VIPomas may invade or metastasize

Some VIP-producing tumors are locally invasive.

Some develop metastatic disease.

Functional symptoms do not establish whether the lesion is localized.

Separate assessments

Secretory phenotype ≠ histologic grade ≠ anatomic stage.

Slide 42 · Clinical application: VIPoma syndrome

Teaching vignette

A patient has persistent severe watery secretory diarrhea and hypokalemia. Gastric acid secretion is absent. A pancreatic or extra-pancreatic neuroendocrine source is under investigation.

Diagnostic question

Which hormone assay is prioritized by the described syndrome?

Answer: Plasma VIP assay

WDHA identifies the source-described VIP-associated syndrome. • The excerpt specifically recommends VIP measurement in severe secretory diarrhea.

Slide 43 · VIPoma vs gastrinoma: Opposite gastric acid phenotypes

VIPoma

Achlorhydria is included in WDHA.

Diarrhea is a central clue.

VIP assay addresses hormone excess.

Gastrinoma

Acid hypersecretion drives peptic ulceration.

Ulcers can be multiple, refractory or unusually situated.

Elevated gastrin defines the hormone syndrome.

Slide 44 · Serotonin-producing pancreatic tumors are extremely rare

Pancreatic serotonin-producing carcinoid tumors as exceedingly rare.

They may cause an atypical carcinoid syndrome.

This represents a minority phenotype within pancreatic endocrine neoplasia.

Slide 45 · “Pancreatic carcinoid” is a phenotype-based term

What the textbook reports

A pancreatic tumor may produce serotonin.

An atypical carcinoid syndrome can result.

The entity is exceedingly rare.

What not to infer

Not every PanNEN secretes serotonin.

Not every pancreatic endocrine mass causes carcinoid symptoms.

“Atypical” is not itself a grade designation here.

Slide 46 · Clinical application: Serotonin-associated phenotype

Teaching vignette

A pancreatic endocrine neoplasm is documented to secrete serotonin and is associated with an atypical carcinoid syndrome.

Diagnostic question

How should this endocrine phenotype be classified from the supplied source?

Answer: Exceedingly rare serotonin-producing pancreatic endocrine tumor

The syndrome and hormone are the defining clues in this excerpt. • The source does not provide grading, diagnostic thresholds or detailed symptoms.

Slide 47 · Pancreatic polypeptide tumors: Secretion without syndrome

Endocrine tumor

Pancreatic polypeptide secretion

High plasma hormone

May be present without endocrine symptoms

Clinical presentation

A mass lesion rather than a recognizable syndrome

Slide 48 · A hormone concentration is not always a functional syndrome

Pancreatic polypeptide-secreting tumor

Plasma pancreatic polypeptide may be high.

Even high levels fail to cause a syndrome.

Mass effect or mass detection drives presentation.

Clinically functional rare tumor

Glucagonoma: Recognizable skin/metabolic pattern.

Somatostatinoma: Metabolic/GI constellation.

VIPoma: Severe secretory diarrhea syndrome.

Slide 49 · Why a mass lesion can be the first clue

Pancreatic polypeptide-secreting neoplasms may be clinically silent hormonally.

Without a characteristic endocrine syndrome, a lesion can present as a mass.

Hormone production and hormone-mediated symptoms must be recorded separately.

Slide 50 · Clinical application: Hormonally silent presentation

Teaching vignette

A pancreatic endocrine mass is identified. The tumor secretes pancreatic polypeptide, but the patient has no characteristic hormone-excess syndrome.

Diagnostic question

What presentation does Robbins specifically emphasize?

Answer: Presentation as a mass lesion

Even high circulating levels of pancreatic polypeptide need not cause symptoms. • Biochemical secretion should not be mistaken for a clinically functional syndrome.

Slide 51 · One tumor may produce more than one hormone

Single neoplasm

One pancreatic or extrapancreatic endocrine lesion

Multiple hormone products

More than one peptide or amine

Clinical interpretation

Symptoms may reflect combined secretory effects

Slide 52 · Multihormonal tumor is not the same as MEN1

Multihormonal tumor

One tumor may secrete two or more hormones.

Endocrine products originate from the same neoplasm.

A syndrome may combine multiple hormone effects.

Multiple endocrine neoplasia

More than one endocrine gland may harbor neoplasia.

Different tumors may secrete different hormones.

The anatomic multiplicity is the discriminating concept.

Slide 53 · Syndrome-based differential: First-pass assessment

Presenting pattern

Best source-linked subtype

Useful focused laboratory clue

Rash + mild diabetes + anemia

Glucagonoma

Marked plasma glucagon elevation

Diabetes + gallstones + steatorrhea

Somatostatinoma

Elevated plasma somatostatin

Severe watery diarrhea + hypokalemia

VIPoma / VIP syndrome

VIP assay

Serotonin + atypical carcinoid syndrome

Rare serotonin-producing tumor

No cutoff provided in excerpt

Pancreatic mass, no hormonal syndrome

Pancreatic polypeptide tumor possible

No symptomatic polypeptide syndrome

Slide 54 · Reason in two stages: Syndrome, then lesion

Clinical pattern

Recognize defining symptom cluster

Biochemical support

Measure relevant hormone when source specifies

Tumor characterization

Localize, grade and assess spread independently

Slide 55 · Hormonal phenotype does not determine oncologic status

Phenotype question

Tumor behavior question

Which hormone(s) are secreted?

Is differentiation well or poor?

Are there clinical hormone effects?

What is mitotic / Ki-67 proliferation?

What syndrome identifies the tumor?

Is there local invasion or metastasis?

Which hormone assay is indicated?

Can appearance alone predict outcome? No.

Slide 56 · Applied differential: Three contrasting presentations

Teaching vignette

Three hypothetical patients: A) skin eruption, anemia and mild diabetes; B) watery diarrhea and hypokalemia; C) asymptomatic hormone-secreting pancreatic mass.

Diagnostic question

Match each presentation to the most likely source-described phenotype.

Answer: A: Glucagonoma · B: VIPoma · C: Pancreatic polypeptide-secreting tumor

The strongest clue is the syndrome–hormone pairing. • A mass with hormone secretion but no syndrome is not equivalent to a functional tumor.

Slide 57 · Comparative reference: Five rare phenotypes

Tumor

Core clue

Hormone

Nuance

Glucagonoma

NME + diabetes + anemia

Glucagon

Described especially in peri/postmenopausal females

Somatostatinoma

Diabetes + gallstones + steatorrhea

Somatostatin

Difficult preoperative localization

VIPoma

WDHA

VIP

Other nonpancreatic tumors may secrete VIP

Serotonin-producing

Atypical carcinoid syndrome

Serotonin

Exceedingly rare

Pancreatic polypeptide

Mass lesion

Pancreatic polypeptide

No syndrome despite high hormone level

Slide 58 · Five distinctions to retain

Glucagonoma: Necrolytic migratory erythema links dermatology to an endocrine neoplasm.

Somatostatinoma: Diabetes + cholelithiasis + steatorrhea + hypochlorhydria.

VIPoma: Watery diarrhea, hypokalemia and achlorhydria warrant VIP testing.

Serotonin-producing tumors are exceedingly rare; Polypeptide-secreting tumors may be clinically silent.

Critical distinction

Secretory syndrome and tumor aggressiveness are different diagnostic dimensions.

Slide 59 · Reference and scope

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition, 2026.

Core section: “Other Rare Pancreatic Endocrine Neoplasms.”

PanNEN biology and insulinoma/gastrinoma comparisons draw on the adjacent textbook sections.

Detailed clinical testing thresholds and current management algorithms require dedicated specialist references.